Abl Bio Inc.

Legochem Biosciences, Inc.

Jinhyung Ahn

Byungje Sung

Juhee Kim

Eunsil Sung

Yeunju Kim

Kyungjin Park

Daehae Song

Yangsoon Lee

Hyejin Chung

Youngdon Pak

Donghoon Yeom

Jaehyun Eom

Dongin Kim

Sang Hoon Lee

Bora Lee

Eunyoung Park

Kyeongsu Park

Yong-Gyu Son

Jiseon Yoo

Jaeho Jung

Jinwon Jung

Sungwon An

Seung-Jae Lee

Tae Kyung Kim

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Hyoung Rae Kim

Kyung Eun Park

Dae Hyuck Kang

Chang Sun Lee

Yun-Hee Park

Ji Hye Oh

Seawon Ahn

Uijung Jung

Minji Park

Ui-Jung Jung

Hyeun Joung Lee

Hyun Min Ryu

JinWon Jung

Weonkyoo You

Yonggyu Son

Ju Yuel Baek

Young-Jae Yang

Sang-Jun Ha

Myeong Joon Kim

Min Sun Choi

Nara Han

Yoseob Lee

Ji-Na You

Youngeun Hong

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

The disclosure discloses anti α-Syn antibodies preferentially recognizing α-Syn aggregates. The antibodies of the present invention bind to α-Syn aggregates with high affinity and specificity and inhibit accumulation or intercellular transfer of α-Syn aggregates, and thus can be used for detection, diagnosis and/or treatment or prevention of various diseases caused by the accumulation of α-Syn aggregates.

Anti-alpha-synuclein antibodies and uses thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

Growing community of inventors

Seongnam-si, South Korea

Jinhyung Ahn